Every year, BMC Medicine publishes several systematic reviews that can inform evidence-based interventions, treatment approaches, and policies within clinical and/or population health settings, and across a variety of countries and global issues. Below is a list of recent systematic reviews that may be of interest to our readership and other key stakeholders in designing clinical or global health interventions.
Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (E...
Citation: BMC Medicine 2017 15:193